ConductScience.org, home

Paper39201418

Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches.

Ferdous SE and 1 other. Int J Mol Sci, 2024. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches. Papers, record 39201418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39201418

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
6.94, provisional
iCite
Revised in PubMed
2025-08-16
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ferdous SEShifat-E
2Ferrell JMJessica Mhttps://orcid.org/0000-0003-3691-3330

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Humans
Animals
Metabolic Syndrome
Insulin Resistance
Fatty Liver
Non-alcoholic Fatty Liver Disease

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AA015951NIAAA NIH HHSUnited StatesR01AA015951PubMed and NIHNIH RePORTER
1R01AA015951-17A1NIH HHSUnited StatesR01AA015951PubMed and NIHNIH RePORTER
R56 DK044442NIDDK NIH HHSUnited StatesR01DK044442PubMed and NIHNIH RePORTER
R01 DK044442NIDDK NIH HHSUnited StatesR01DK044442PubMed and NIHNIH RePORTER
1R01DK044442-26A1NIH HHSUnited StatesR01DK044442PubMed and NIHNIH RePORTER

Download CSV of grants

References95

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135325622Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35325622PubMed
237230214Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD.Metabolism2023https://conductscience.org/library/papers/37230214PubMed
332019723A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.J Diabetes Complications2020https://conductscience.org/library/papers/32019723PubMed
426399788GPR119: a promising target for nonalcoholic fatty liver disease.FASEB J2016https://conductscience.org/library/papers/26399788PubMed
538521116The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.Clin Gastroenterol Hepatol2024https://conductscience.org/library/papers/38521116PubMed
625512491Identification of S-nitroso-CoA reductases that regulate protein S-nitrosylation.Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/25512491PubMed
723017715Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism.Vitam Horm2012https://conductscience.org/library/papers/23017715PubMed
830158026Recent insights into the role of ChREBP in intestinal fructose absorption and metabolism.BMB Rep2018https://conductscience.org/library/papers/30158026PubMed
937088458Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.Clin Gastroenterol Hepatol2024https://conductscience.org/library/papers/37088458PubMed
1030605011Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.Am J Physiol Gastrointest Liver Physiol2019https://conductscience.org/library/papers/30605011PubMed
1131697972Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.J Hepatol2020https://conductscience.org/library/papers/31697972PubMed
1229358469Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis.Diabetes Care2018https://conductscience.org/library/papers/29358469PubMed
1334956080Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34956080PubMed
1433724511Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.Hepatology2021https://conductscience.org/library/papers/33724511PubMed
1527639537Clinical relevance of the bile acid receptor TGR5 in metabolism.Lancet Diabetes Endocrinol2017https://conductscience.org/library/papers/27639537PubMed
1636866389Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.JHEP Rep2023https://conductscience.org/library/papers/36866389PubMed
1716410358Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.Proc Natl Acad Sci U S A2006https://conductscience.org/library/papers/16410358PubMed
1835581956Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.Hepatol Commun2022https://conductscience.org/library/papers/35581956PubMed
1922431203The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.J Pharmacol Exp Ther2012https://conductscience.org/library/papers/22431203PubMed
2024583089Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators.Pharmacol Ther2014https://conductscience.org/library/papers/24583089PubMed

See all 95 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
42613422Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42613422PubMed
42510904Centella Asiatica Alleviates Type 2 Diabetes-Related Hepatic Glycolipid Disorders via Regulating UPP1-Mediated Pyrimidine Metabolism.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42510904PubMed
42505401Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives.Cells2026https://conductscience.org/library/papers/42505401PubMed
42461275Imaging of MASLD: clinical standards and novel methods.Diabetologia2026https://conductscience.org/library/papers/42461275PubMed
42416572Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42416572PubMed
42305303Biomarkers for early identification of metabolic dysfunction-associated steatotic liver disease (MASLD): a narrative review.Arch Med Sci2026https://conductscience.org/library/papers/42305303PubMed
42278284Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.Int J Mol Sci2026https://conductscience.org/library/papers/42278284PubMed
42265657Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease.BMC Endocr Disord2026https://conductscience.org/library/papers/42265657PubMed
42242850Association between uric acid to high-density lipoprotein cholesterol ratio (UHR) and osteoporosis in type 2 diabetes with MASLD.Asia Pac J Clin Nutr2026https://conductscience.org/library/papers/42242850PubMed
42072294Type 2 Diabetes Mellitus as a Multisystem Disease: From Insulin Resistance to Organ Crosstalk-A Narrative Review.Biomedicines2026https://conductscience.org/library/papers/42072294PubMed
42005636Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review.Health Sci Rep2026https://conductscience.org/library/papers/42005636PubMed
41928145Demographic profiles and disparities in all liver diseases and diabetes mellitus patients - related mortality among older adults (≥ 65) in the United States, 1999 to 2020.BMC Gastroenterol2026https://conductscience.org/library/papers/41928145PubMed
41835376Gentiopicroside alleviates type 2 diabetes mellitus by attenuating oxidative stress and reshaping gut microbiota in high-fat diet and streptozotocin-induced mice.Front Nutr2026https://conductscience.org/library/papers/41835376PubMed
41767367A pilot study on a combined non-invasive screening test for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/41767367PubMed
41749862Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers (Basel)2026https://conductscience.org/library/papers/41749862PubMed
41635536Synergistic therapeutic strategies for metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus: molecular insights and clinical advances.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41635536PubMed
41507142Multicompartment hydrogel microcapsules for creating spatially patterned cell co-cultures.Microsyst Nanoeng2026https://conductscience.org/library/papers/41507142PubMed
41441969Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study.Diabetes Ther2026https://conductscience.org/library/papers/41441969PubMed
41398609Association between De Ritis ratio and mortality in individuals with diabetes or prediabetes: evidence from NHANES (1999-2018).Eur J Med Res2025https://conductscience.org/library/papers/41398609PubMed
41334445Microbiome-mediated crosstalk between T2DM and MASLD: a translational review focused on function.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/41334445PubMed

See all 32 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39201418

GET https://conductscience.org/api/papers/v1/39201418/references?page=2